JIPYONG LLC

Jipyong News|News

Jipyong and Jipyong IP Sign MOU with Xlife Sciences and Co-Host NASDAQ Listing Seminar for Pharmaceutical and Biotech Companies

2025.06.11

On June 11, Jipyong and Jipyong IP signed a Memorandum of Understanding (MOU) with a Swiss-listed investment company Xlife Sciences AG (“Xlife”) and jointly hosted a seminar on NASDAQ listing for pharmaceutical and biotechnology companies.   
 
The MOU was signed in aims to support the global expansion of Korea’s pharmaceutical and biotechnology sector by leveraging Xlife’s expertise in investing across life science industries, strategically partnered with Jipyong who had been leading the domestic IPO legal advisory market.   
 
The signing ceremony was attended by Jipyong’s Mr. Haeng Gyu LEE, Co-Managing Partner of Jipyong, along with attorneys Mr. Beom Hee KIM, Mr. Jae Chul LEE, Mr. Jin Ha KIM, Ms. Jin Joo JEONG, and Ms. Yu Jin LEE; and Jipyong IP’s Managing Patent Attorney Mr. Hyuk Sung KWON along with patent attorneys Mr. Sung Soo BAE, and Ms. Ji Eun PARK.  Representatives from Xlife included David L. Deck, Chairman of the board of directors; Oliver R. Baumann, CEO; Dr. Alexander Zink, CSO; and Jeong Hwan PARK, the designated Representative Director of Xlife Korea.  Christoph Antz, CEO of VERAXA, and Dr. Roman Rocke, CEO of r2 Advisors, also joined the event.   
 
Following the signing of the MOU, was a seminar titled “Fundraising and Exit Strategies through NASDAQ Listing for Domestic Pharmaceutical and Biotechnology Companies”.  The seminar was hosted by Mr. Beom Hee KIM, Partner and Head of Jipyong’s Technology Center.  Opening remarks were delivered by Mr. Haeng Gyu LEE, Co-Managing Partner of Jipyong, and Mr. Hyuk Sung KWON, Managing Patent Attorney of Jipyong IP.  Subsequently, Ms. Yu Jin LEE, Partner at Jipyong, presented on the “Current Status and Issues of Domestic Pharmaceutical and Biotechnology Companies’ IPOs.”   
 
Oliver R. Baumann, CEO of Xlife, presented on “Identifying NASDAQ Unicorn Opportunities and Development Approaches”, and Dr. Christoph Antz, CEO of VERAXA, a Swiss oncology drug development company, presented on the “Key Factors for Growing from a Small Laboratory Initiative to a Unicorn.”  The seminar concluded with a presentation by Mr. Jae Chul LEE, Senior Foreign Attorney at Jipyong, on the topic of “Practical Aspects of NASDAQ Listings and SPAC Mergers.”   
 
Mr. Haeng Gyu LEE stated, “Through this seminar, we hope that the domestic pharmaceutical and biotechnology companies and venture capitalists will expand their global networks beyond the domestic IPO market and explore opportunities for additional funding and investment exit using the NASDAQ market.”  He further added, “Together with Jipyong IP, Jipyong will continue to support the growth of the Korean pharmaceutical and biotechnology industry as well as the successful investment and exit of related venture capital firms.”   
 
Jipyong has been recognized as the leading legal advisor for domestic IPOs for five consecutive years from 2019 to 2023.  In 2024, we established Jipyong IP to provide comprehensive services related to intellectual property and technology law.  Meanwhile, Xlife successfully listed VERAXA on NASDAQ and is establishing a subsidiary (with Jeong Hwan PARK designated as Representative Director) to actively enter the Korean market.

<div style="text-align: justify;"> 
 
[Photos]  
<img alt="" height="1525" src="https://www.jipyong.com/uploads/editor/image/2025/06/20250612071734_250611_mou_seminar.png" width="806" /></div>

News Jipyong Opens Continued Listing Advisory Center for Listed Companies 2025.03.05

Back to List

Professionals

SHARE

Disclaimer

Limited Liabilities